We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

21 hedge funds and large institutions have $345M invested in China Biologic Products Holdings, Inc. in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

26% more capital invested

Capital invested by funds: $273M → $345M (+$72M)

17% more funds holding

Funds holding: 1821 (+3)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

Holders
21
Holders Change
+3
Holders Change %
+16.67%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
5
Reduced
6
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
WP
1
Warburg Pincus
New York
$321M
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$5.16M
HSBC Holdings
3
HSBC Holdings
United Kingdom
$4.38M
Invesco
4
Invesco
Georgia
$3.07M +$340K +13,660 +15%
Renaissance Technologies
5
Renaissance Technologies
New York
$2.76M +$242K +9,700 +11%
BIT
6
BlackRock Institutional Trust
California
$2.67M -$471K -18,892 -17%
VAM
7
Visium Asset Management
New York
$1.17M
LBA
8
Letko, Brosseau & Associates
Quebec, Canada
$961K +$820K +32,900 New
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$949K +$34.9K +1,400 +5%
GCP
10
GSA Capital Partners
United Kingdom
$815K +$69.8K +2,800 +11%
ACM
11
Ativo Capital Management
Illinois
$664K +$567K +22,746 New
New York State Common Retirement Fund
12
New York State Common Retirement Fund
New York
$467K +$399K +16,000 New
SIM
13
Spark Investment Management
New York
$454K -$292K -11,700 -43%
Morgan Stanley
14
Morgan Stanley
New York
$258K -$349K -14,011 -61%
BG
15
BlackRock Group
United Kingdom
$211K +$180K +7,230 New
RA
16
Royce & Associates
New York
$85K
BA
17
BlackRock Advisors
Delaware
$49K -$87.1K -3,494 -68%
TRCT
18
Tower Research Capital (TRC)
New York
$38K -$12.7K -508 -28%
BJ
19
BlackRock Japan
Japan
$29K -$37.4K -1,500 -60%
OA
20
OFI Advisors
Pennsylvania
$6K +$648 +26 +14%
Bank of America
21
Bank of America
North Carolina
$3K +$2.49K +100 New
PP
22
PDT Partners
New York
-$563K -24,531 Closed
Citigroup
23
Citigroup
New York
-$2K -72 Closed

CBPO Hedge Fund Activity: Q3 2013 in Review

21 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2013, worth a combined $345M — up 26% from $273M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CBPO positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Letko, Brosseau & Associates, opening a new position worth an estimated $820K. The largest seller was PDT Partners, exiting entirely with an estimated $563K sold.

  • 21 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2013, up from 18 in Q2 2013.
  • Funds reported $345M of China Biologic Products Holdings, Inc. stock for Q3 2013, up 26% quarter-over-quarter.
  • 5 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2013 and 2 closed out, a net change of +3 holders.
  • The largest China Biologic Products Holdings, Inc. buyer in Q3 2013 was Letko, Brosseau & Associates, an estimated $820K added.
  • The largest China Biologic Products Holdings, Inc. seller in Q3 2013 was PDT Partners, an estimated $563K sold.

Based on aggregated 13F filings for Q3 2013.